Investors aiming to benefit from large price gains frequently use a two-part method, merging the prospective focus of fundamental analysis with the timing cues from technical analysis. One specific tactic looks for solid growth stocks that are also showing encouraging technical breakout formations. The idea is simple: find firms with sound and quickening business basics, like earnings growth, profitability, and financial condition, and then watch for the market's price movement to indicate a possible rise. This technique tries to match a company's internal growth path with a good starting point shown by the charts, which may improve the chance of a profitable investment.
BOSTON SCIENTIFIC CORP (NYSE:BSX) offers an interesting example for this tactic. The medical device leader, recognized for its new products in cardiology, endoscopy, urology, and neuromodulation, has shown the sort of operational quality that growth investors look for.
Fundamental Strength: The Engine for Growth
A close look at the company's fundamental analysis report shows a business performing well. The total fundamental score of 7/10 is supported by high marks in profitability and financial health, which are important for maintaining long-term growth without high risk.
- High Profitability (Score: 9/10): Boston Scientific is not only expanding, it is expanding with profit. Important measures are much better than industry counterparts:
- Profit Margin: At 14.44%, it is higher than almost 90% of its Health Care Equipment & Supplies industry rivals.
- Return on Equity & Invested Capital: An ROE of 11.96% and an ROIC of 8.70% both put the firm in the top 15% of its field, showing very effective use of investor capital.
- Good Financial Health (Score: 7/10): The company keeps a strong balance sheet, essential for enduring economic changes and paying for future development.
- Its Altman-Z score of 3.94 points to a very small short-term chance of financial trouble.
- A reasonable Debt/Equity ratio of 0.46 and a good Debt-to-Free-Cash-Flow ratio of 3.13 show a careful use of debt.
- Good and Steady Growth (Score: 7/10): This is the center of the growth argument. Boston Scientific has produced notable results and is predicted to stay on a firm course.
- Past Results: In the last year, EPS increased by a notable 21.5% and Revenue by 19.9%. The 5-year average yearly EPS growth is a high 26%.
- Future Predictions: Experts forecast continued good growth, with expected average yearly EPS growth of 13.1% and Revenue growth of 10.5% moving ahead.
This fundamental picture fits exactly with the growth stock standards noted in our opening section. The company works in the large and constantly advancing medical technology sector, has gained top market position in several important treatment areas, and is turning that position into better profitability and steady, above-normal growth.
Technical Setup: The Market's Signal
While fundamentals explain the "why," technical analysis can help find the "when." Based on the technical analysis report, BSX is now showing what is called a consolidation or setup formation, receiving a Setup Score of 7/10.
The stock has seen a large drop from its 52-week peaks, which has hurt its short- and long-term trend scores. However, this drop has now lessened, and the price has started to trade in a narrower band with lower price swings. This kind of price activity often comes before a new price move. Importantly, the report finds a clear and close resistance area between $64.24 and $64.90, made from a mix of trend lines and moving averages.
For investors using the combined tactic, this setup is important. A clear move above this resistance area on high trading volume could indicate that the time of consolidation is finished and that buying interest is returning, possibly giving a technically-marked starting point that matches the strong fundamental narrative.
Valuation Context
Even with its good growth, BSX does not seem extremely overpriced. Its Price/Earnings ratio of 21.1 is lower than the present S&P 500 average. More significantly, its Price/Forward Earnings ratio of 18.4 is less expensive than over 83% of its industry peers. When growth, profitability, and industry standing are weighed, the valuation can be seen as fair, particularly if the company keeps performing on its growth forecasts.
Conclusion
Boston Scientific Corp represents the kind of firm sought by a growth-with-technical-setup tactic. Its fundamental report shows a frontrunner in a crucial field, producing high profitability, keeping financial soundness, and achieving steady double-digit growth. The technical view, while showing past declines, now shows the stock forming a consolidation formation just under a set resistance point. A move above this point could be seen as a confirming sign that the market is prepared to value the stock upward, matching price movement with the basic business movement.
This review of BSX was found using a particular filter for Strong Growth Stocks with good Technical Setup Scores. You can review other stocks now meeting this combined fundamental and technical standard by viewing the full filter results here.
Disclaimer: This article is for information and learning only and does not form investment guidance, a suggestion, or an offer or request to buy or sell any securities. The information given is based on supplied data and should not be the only foundation for any investment choice. All investing includes risk, including the possible loss of the original amount invested. Past results do not ensure future outcomes. You should do your own investigation and talk with a certified financial consultant before making any investment choices.